4 recruiting, 1 completed, 1 not yet recruiting, 1 withdrawn. 7 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Recruiting 4, Completed 1, Not yet recruiting 1, Withdrawn 1 |
| Phase 1 | 4 | Recruiting 2, Completed 1, Withdrawn 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Refractory AML: new trials by email Literature Review of Refractory AML trials Research Report on Refractory AML
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT AdaptNK, Fludarabine, Cyclophosphamide - Relapsed Adult AML, Refractory AML | Phase 1 / Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 18 | 2026-05-08 | 2026-05-19 |
| Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML 131I-apamistamab, Fludarabine, Cyclophosphamide - Acute Leukemia, Myeloid Leukemia | Phase 2 / Phase 3 | Not yet recruiting | Actinium Pharmaceuticals | 306 | 2026-01-01 | 2025-09-10 |
| Tislelizumab with Azacitidine in the Treatment of R/R AML Aza, tislelizumab - Refractory AML, Relapsed Adult AML | Phase 1 / Phase 2 | Withdrawn | Institute of Hematology & Blood Diseases Hospital, China | 2024-10-05 | 2024-09-19 | |
| Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation Avapritinib, Azacitidine Injection, Decitabine Injection - AML, Childhood, Relapse/Recurrence | Phase 2 | Recruiting | Children's Hospital of Soochow University | 50 | 2024-03-01 | 2024-08-22 |
| Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia AzaCITIDine Oral Tablet, Xospata - AML, Adult, Refractory AML | Phase 2 | Recruiting | French Innovative Leukemia Organisation | 33 | 2024-01-13 | 2025-03-24 |
| Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX) Venetoclax Oral Tablet - Relapsed Adult AML, Refractory AML | Phase 1 / Phase 2 | Completed | Technische Universität Dresden | 55 | 2020-04-06 | 2026-09-02 |
| Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia Tuspetinib, Venetoclax Oral Tablet, Azacitidine for Intravenous Infusion - Leukemia, Myeloid, Acute, Refractory AML | Phase 1 / Phase 2 | Recruiting | Aptose Biosciences Inc. | 240 | 2019-03-11 | 2025-08-26 |
Leukemia, Myeloid, Acute (7) · Recurrence (2) · Leukemia (1) · Leukemia, Myeloid (1) · Leukemia, Myelomonocytic, Chronic (1)
Hematologic Diseases (7) · Hemic and Lymphatic Diseases (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Leukemia (6) · Leukemia, Myeloid (6) · Disease Attributes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Bone Marrow Diseases (1) · Chronic Disease (1) · Myelodysplastic-Myeloproliferative Diseases (1)
Azacitidine (3) · Cyclophosphamide (2) · fludarabine (2) · venetoclax (2) · Cytarabine (1) · Decitabine (1) · Granulocyte Colony-Stimulating Factor (1) · Idarubicin (1) · Infusions, Intravenous (1) · Interleukin-2 (1) · Whole-Body Irradiation (1) · avapritinib (1) · cc-486 (1) · gilteritinib (1) · tislelizumab (1)
Actinium Pharmaceuticals (1) · Aptose Biosciences Inc. (1) · Children's Hospital of Soochow University (1) · French Innovative Leukemia Organisation (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Masonic Cancer Center, University of Minnesota (1) · Technische Universität Dresden (1)
China (2) · Germany (2) · United States (2) · Australia (1) · France (1) · New Zealand (1) · South Korea (1) · Spain (1)
Naval Daver, MD (1) · Shaoyan Hu, MD, PhD (1)
2023 (1)